
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne has demonstrated strong financial performance, reporting 9% organic growth in FQ2'25 driven by increased spending in the pharma and biotech sectors, resulting in a revenue beat of approximately 4%. The company's Protein Sciences and Diagnostics & Spatial Biology segments exhibited robust year-over-year growth rates of 8% and 12% respectively, underpinned by a favorable biopharmaceutical market and advancing cell therapy programs. Market trends indicate a positive trajectory with projected improvements in demand from biopharma customers, signaling potential for sustained revenue growth and enhanced profit margins in the future.
Bears say
Bio-Techne faces significant risks that may contribute to a negative outlook on its stock, including potentially overestimated revenue and earnings forecasts due to lower-than-anticipated demand for its products. The company is experiencing supply chain challenges, leading to inflated inventories and reduced equipment sales, with the slowdown in small biotech purchasing posing additional risks to future revenue. Furthermore, Bio-Techne's competitive position is threatened by larger, better-financed competitors and macroeconomic factors, including prolonged end-market weakness in life science tools and diagnostics, which could adversely impact future revenue and profitability.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares